Clinical Trial Update: A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing the pharmacodynamics and safety evaluation of ARCT-810 in participants with ornithine transcarbamylase deficiency (OT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency

Drugs mentioned

• ARCT-810

Snippet

Sponsor: Arcturus Therapeutics, Inc. | Conditions: OTC Deficiency, Ornithine Transcarbamylase Deficiency | Phase 2 | Status: RECRUITING